A H Ko

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
    Clin Cancer Res 22:61-8. 2016
  2. doi request reprint Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities
    Andrew H Ko
    From the University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
    J Clin Oncol 33:1779-86. 2015
  3. pmc Erlotinib in the treatment of advanced pancreatic cancer
    Robin K Kelley
    University of California, San Francisco, Comprehensive Cancer Center
    Biologics 2:83-95. 2008
  4. pmc A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
    A H Ko
    Division of Hematology Oncology, Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Br J Cancer 109:920-5. 2013
  5. doi request reprint A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94115, USA
    Cancer Chemother Pharmacol 70:875-81. 2012
  6. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
  7. doi request reprint A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Invest New Drugs 30:1597-606. 2012
  8. ncbi request reprint Current and future strategies for combined-modality therapy in pancreatic cancer
    Andrew H Ko
    Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 4:202-12. 2002
  9. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
  10. doi request reprint A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008

Detail Information

Publications34

  1. pmc A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
    Clin Cancer Res 22:61-8. 2016
    ....
  2. doi request reprint Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities
    Andrew H Ko
    From the University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
    J Clin Oncol 33:1779-86. 2015
    ....
  3. pmc Erlotinib in the treatment of advanced pancreatic cancer
    Robin K Kelley
    University of California, San Francisco, Comprehensive Cancer Center
    Biologics 2:83-95. 2008
    ..This article reviews the evidence supporting EGFR inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications of targeted therapy in this challenging malignancy...
  4. pmc A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
    A H Ko
    Division of Hematology Oncology, Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Br J Cancer 109:920-5. 2013
    ..PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cancer...
  5. doi request reprint A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94115, USA
    Cancer Chemother Pharmacol 70:875-81. 2012
    ....
  6. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  7. doi request reprint A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Invest New Drugs 30:1597-606. 2012
    ..To our knowledge, this is one of the first trials to evaluate a completely noncytotoxic regimen in the first-line treatment of advanced pancreatic cancer. (ClinicalTrials.gov number, NCT00326911)...
  8. ncbi request reprint Current and future strategies for combined-modality therapy in pancreatic cancer
    Andrew H Ko
    Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 4:202-12. 2002
    ....
  9. doi request reprint A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  10. doi request reprint A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
    ..The objectives of this study were to determine safety and efficacy in chemotherapy-naive patients with metastatic pancreatic cancer receiving bevacizumab in combination with fixed-dose rate (FDR) gemcitabine and low-dose cisplatin...
  11. doi request reprint Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Invest 26:47-52. 2008
    ..We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease...
  12. ncbi request reprint Future strategies for targeted therapies and tailored patient management in pancreatic cancer
    Andrew H Ko
    Department of Medicine, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Semin Oncol 34:354-64. 2007
    ..A newer strategy worth pursuing involves tailoring an individual patient's therapy according to the molecular characteristics of both host and tumor, as has shown promise in other solid tumor types...
  13. ncbi request reprint A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
    ..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
  14. ncbi request reprint Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 24:379-85. 2006
    ..The objectives of this study were to determine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabine in combination with low-dose cisplatin...
  15. ncbi request reprint Treatment of metastatic pancreatic cancer
    Andrew H Ko
    Division of Medical Oncology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    J Natl Compr Canc Netw 3:627-36. 2005
    ..This article provides the evidence to support each of these approaches and highlights future directions in the management of metastatic pancreatic cancer...
  16. ncbi request reprint Systemic therapy for pancreatic cancer
    Andrew H Ko
    San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    Semin Radiat Oncol 15:245-53. 2005
    ..The combination of standard cytotoxic agents and these newer targeted compounds offers promise that we will be able to make significant inroads in improving clinical outcomes for patients with advanced pancreatic cancer...
  17. pmc Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
    A H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Br J Cancer 93:195-9. 2005
    ....
  18. ncbi request reprint Clinical outcomes associated with very late relapses in diffuse large cell lymphoma
    Andrew H Ko
    Division of Hematology Oncology, University of California, San Francisco Medical Center, San Francisco, CA 94115, USA
    Leuk Lymphoma 43:1789-93. 2002
    ..The overall poor prognosis in this group of patients justifies the use of more aggressive treatment approaches in the future, such as high dose therapy with stem cell support, rather than conventional salvage chemotherapy regimens...
  19. ncbi request reprint Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors
    E K Bergsland
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA University of California San Francisco, San Francisco, CA
    J Clin Oncol 26:14620. 2008
    ....
  20. ncbi request reprint A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer
    A H Ko
    University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA National Cheng Kung University Hospital, Tainan, Taiwan National Taiwan University Hospital, Taipei, Taiwan University of California, San Francisco, San Francisco, CA PharmaEngine, Inc, Taipei, Taiwan National Health Research Institutes, National Cheng Kung University, National Cheng Kung University Hospital, Kaohsiung Medical University Hospital, Tainan, Taiwan
    J Clin Oncol 29:237. 2011
    ..This phase II study aims to evaluate PEP02 monotherapy as 2nd-line treatment in pts with metastatic, GEM-refractory PC...
  21. ncbi request reprint Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    R K Kelley
    University of California, San Francisco, San Francisco, CA Northwestern University Feinberg School of Medicine, Chicago, IL Northwestern Medical Faculty Foundation, Chicago, IL University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA
    J Clin Oncol 29:296. 2011
    ..The study was approved and funded by the National Comprehensive Cancer Network (NCCN)...
  22. pmc A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
    R K Kelley
    Department of Medicine, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1700, San Francisco, CA 94143, USA
    Br J Cancer 109:1725-34. 2013
    ..This phase 1 clinical trial was conducted to determine the safety, maximum-tolerated dose (MTD), and pharmacokinetics of imatinib, bevacizumab, and metronomic cyclophosphamide in patients with advanced colorectal cancer (CRC)...
  23. doi request reprint Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy
    Derrick Wong
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Pancreas 37:269-74. 2008
    ..Serum carbohydrate antigen 19-9 (CA19-9) has never been compared to radiographic objective response as a surrogate for clinical outcomes in patients receiving chemotherapy for metastatic pancreatic cancer...
  24. ncbi request reprint Biliary stent complications in clinical trials for advanced pancreatic cancer
    A M Espinoza
    University of California, San Francisco, San Francisco, CA University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA University of California, San Francisco UCSF, San Francisco, CA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
    J Clin Oncol 29:e14665. 2011
    ..NCCN guidelines recommend metal stents because of a lower occlusion rate. We did a retrospective analysis of biliary stent outcomes in pts with advanced pancreatic cancer (APC) who were treated on a series of phase II trials at UCSF...
  25. ncbi request reprint Phase I trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors
    E K Bergsland
    University of California San Francisco, San Francisco, CA
    J Clin Oncol 26:15026. 2008
    ....
  26. ncbi request reprint A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
    A H Ko
    University of California San Francisco, San Francisco, CA
    J Clin Oncol 26:4516. 2008
    ..We conducted a phase II study to evaluate the safety and efficacy of the combination of BEV and ERL in pts with GEM-refractory MPC...
  27. ncbi request reprint Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors
    A P Venook
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
    J Clin Oncol 26:15545. 2008
    ..We performed a prospective, phase II study to assess the safety and efficacy of mFOLFOX-6 plus bevacizumab (BV) in patients (pts) with advanced, progressive NET...
  28. pmc Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
    R K Kelley
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco UCSF, San Francisco, CA 94143, USA
    Ann Oncol 24:1900-7. 2013
    ....
  29. pmc A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
    Amy J Chien
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:5569-75. 2009
    ..This study investigates the clinical relevance of this approach...
  30. ncbi request reprint A phase I dose escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced cancer
    A J Chien
    University of California San Francisco, San Francisco, CA GalxoSmithKline, Research Triangle Park, NC UCSF Cancer Center Investigators
    J Clin Oncol 26:3595. 2008
    ....
  31. ncbi request reprint A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer
    A H Ko
    University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA National Cheng Kung University Hospital, Tainan, Taiwan National Taiwan University Hospital, Taipei, Taiwan PharmaEngine, Inc, Taipei, Taiwan
    J Clin Oncol 29:4069. 2011
    ..This phase II study aims to evaluate PEP02 monotherapy as second-line treatment in pts with metastatic, GEM-refractory PC...
  32. ncbi request reprint Radiation therapy in operable and locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 8:1022-31. 2010
    ....
  33. ncbi request reprint Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California
    Andrew H Ko
    Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA
    Cancer Causes Control 18:809-19. 2007
    ..To determine the association between pancreatic cancer and medical conditions...
  34. ncbi request reprint Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature
    Andrew H Ko
    Division of Hematology and Oncology, University of California, San Francisco, California 94115, USA
    Dig Dis Sci 48:192-6. 2003